glp 3 retatrutide peptide Reta (GLP-3) research product GLP-3 Retatrutide · Disguised Alpha

How does retatrutide compare to semaglutide and tirzepatide

New combination treatments in the management of diabetes: focus on sitagliptin-metformin

10.1016/j.ejphar.2022.174843 118 SusiniS.RocheE.PrentkiM.SchlegelW

15,20 Although many of these AEs have occurred early in therapy and subsided over time, they remain a primary reason for dose adjustment or discontinuation

Patients with T2D generally experience fewer GI side effects

This medications safety profile has not been studied in patients under the age of 18, pregnant and lactating people, or those with normal BMIs. At the time of publishing, the FDA has only approved three GLP-1 agonists for weight loss: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)